Temoporfin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Temoporfin
Temoporfin.png
Systematic (IUPAC) name
3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
Clinical data
AHFS/Drugs.com International Drug Names
Licence data EMA:Link
Legal status
  • Prescription only
Identifiers
CAS number 122341-38-2 YesY
ATC code L01XD05
PubChem CID 60751
UNII FU21S769PF YesY
KEGG D06066 YesY
ChEMBL CHEMBL383675
Chemical data
Formula C44H32N4O4 
Mol. mass 680.74 g/mol
 YesY (what is this?)  (verify)

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck[1] .[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.[3]

Good results were obtained in 21 of 35 patients treated in Germany.[4]

It is photoactivated at 652 nm[5] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.[2]

Further reading[edit]

References[edit]

  1. ^ Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German) 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041. 
  2. ^ a b O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology. 
  3. ^ http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
  4. ^ http://www.springerlink.com/content/g74w224824v8l013/
  5. ^ "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.